FDA Oncology Announcements

KMT2A inhibitor × Clear all

3 Announcements

FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation

Drug: Komzifti (ziftomenib) · KMT2A inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation

Trial: AUGMENT-101
Drug: Revuforj (revumenib) · KMT2A inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation

Drug: Revuforj (revumenib) · KMT2A inhibitor
Conditions: LymphoidMyeloidOther hematologic neoplasm